• Explore /
  • Poster
  • / Updates from a phase Ib study of isatuximab (Isa), bortezomib (V) and dexamethasone (D) plus cyclophosphamide (C) or lenalidomide (R) in transplant-ineligible, newly diagnosed multiple myeloma (NDMM).

Updates from a phase Ib study of isatuximab (Isa), bortezomib (V) and dexamethasone (D) plus cyclophosphamide (C) or lenalidomide (R) in transplant-ineligible, newly diagnosed multiple myeloma (NDMM).

Abstract Video & Slides Poster

Authors

null

Enrique M. Ocio

Marqués de Valdecilla University Hospital (IDIVAL), University of Cantabria, Santander, Spain

Enrique M. Ocio , Paula Rodríguez Otero , Sara Bringhen , Stefania Oliva , Axel Nogai , Michel Attal , Philippe Moreau , Joaquin Martinez-Lopez , Nadia Le Roux , Sandrine Macé , Marie-Claude Rouchon , Qiuyan Wang , Maria-Victoria Mateos

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT02513186

Citation

J Clin Oncol 38: 2020 (suppl; abstr 8529)

DOI

10.1200/JCO.2020.38.15_suppl.8529

Abstract #

8529

Poster Bd #

429

Abstract Disclosures

Similar Posters

First Author: Shaji Kumar

First Author: Stefania Oliva

First Author: Charlotte Pawlyn

First Author: E. Bridget Kim